Hematologic Malignancy
Central Nervous System Lymphoma
CI-CAN-00000653Explore in graph →
Hematologic81 active trials
- NCIt
- C212063
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000653Explore in graph →
Clinical trials
214 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (15)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06445257 | A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL | unknown | N/A | 30 | Huai'an First People's HospitalOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05117814 | Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma | unknown | N/A | 20 | Peking University People's HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT04845139 |
| A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma |
| unknown |
| N/A |
| 1 |
| Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER |
| 1 |
| Jul 7, 2022 |
| clinicaltrials |
| NCT03582254 | Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years(LOCALYSE) | unknown | N/A | 62 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 10, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jun 6, 2024source: clinicaltrials